Telix Pharmaceuticals Ltd
TLX · XNASCIK 2007191fmd_0JR6J703WREDNT07KYS37N0T9HManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2022 to Dec 31, 2025, 4 periods
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Total revenues | 333 | 517 | 804 |
| Cost of revenue | 123 | 180 | 377 |
| Gross profit | 210 | 336 | 426 |
| Research and development | 85 | 128 | 171 |
| Operating income | 11 | 55 | 30 |
| Interest expense | 9 | 24 | 41 |
| Income before taxes | 3 | 38 | (5) |
| Income tax expense | (2) | 4 | 2 |
| Net income from continuing operations | 4 | 34 | (7) |
| Net income | 4 | 34 | (7) |